Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $277,250.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $22.18, for a total value of $277,250.00. Following the completion of the sale, the chief executive officer now owns 952,892 shares in the company, valued at approximately $21,135,144.56. This represents a 1.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, June 3rd, Samuel Kintz sold 7,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.05, for a total value of $150,375.00.
• On Monday, May 19th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.49, for a total value of $82,450.00.
• On Thursday, May 1st, Samuel Kintz sold 5,330 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.08, for a total value of $107,026.40.
• On Thursday, April 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.42, for a total value of $82,100.00.

Enliven Therapeutics Stock Down 1.1%

NASDAQ ELVN traded down $0.23 during mid-day trading on Wednesday, hitting $21.57. The stock had a trading volume of 423,893 shares, compared to its average volume of 292,627. The firm's 50 day moving average is $18.55 and its 200 day moving average is $20.60. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). Research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ELVN shares. HC Wainwright increased their target price on Enliven Therapeutics from $39.00 to $40.00 and gave the company a "buy" rating in a research report on Thursday, May 15th. The Goldman Sachs Group initiated coverage on Enliven Therapeutics in a research note on Monday. They issued a "buy" rating and a $37.00 price objective for the company. Robert W. Baird increased their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday. Finally, Jones Trading reduced their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $39.60.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC increased its stake in shares of Enliven Therapeutics by 3.2% in the 4th quarter. FMR LLC now owns 6,495,871 shares of the company's stock worth $146,157,000 after acquiring an additional 199,692 shares during the last quarter. Polar Capital Holdings Plc increased its position in shares of Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock worth $53,768,000 after purchasing an additional 1,739,668 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Enliven Therapeutics by 2.9% during the 4th quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock worth $44,452,000 after purchasing an additional 55,283 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Enliven Therapeutics by 27.9% during the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock worth $30,001,000 after purchasing an additional 290,153 shares during the last quarter. Finally, Pictet Asset Management Holding SA increased its position in shares of Enliven Therapeutics by 16.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock worth $21,877,000 after purchasing an additional 135,969 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.